Tout sur Jonsson-Oldenbuettel

Les premières données, après 6 mois de suivi, de l'étude prospective allemande CARLOS nous fournissent, pour la première fois, de précieuses informations en conditions de vie réelle sur l'efficacité, l'adhérence et l'expérience patient du traitement injectable associant cabotegravir et rilpivirine LA.

Partner content ViiV Healthcare

Lire l'article

Live from

Lire les articles

Online e-learning

Real-world treatment adherence and strict inclusion criteria used during RCTs can lead to several patient groups being underrepresented. Therefore, real-world data on DTG-based 2DRs are highly needed to be able to evaluate virologic and safety outcomes in these underrepresented patient groups.In this webinar, Dr. Nasreddine highlighted the outcomes of the BREACH DTG-based 2DR cohort, a retrospective, observational, multicenter study (n=10).Subsequently Prof. De Wit, Chair of the Belgian HIV Research Consortium BREACH, gave his clinical implications of these cohort data.Finally, Dr. De Scheerder provided a comprehensive overview of the real-world DTG/3TC data that are currently available beyond Belgium.

Take the course